Results 211 to 220 of about 90,332 (308)

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy.
Alexander Carpinteiro   +15 more
wiley   +1 more source

Pathogenesis and kidney prognosis of renal amyloidosis. [PDF]

open access: yesCell Mol Life Sci
Hu A, Chowdhury RB, Bianchi G.
europepmc   +1 more source

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract Measurable residual disease assessment in bone marrow (BM‐MRD) is a crucial prognostic factor in multiple myeloma (MM), but its clinical use has some caveats, such as invasiveness, poor spatial representativity, and serial sampling. Novel minimally invasive approaches for monitoring peripheral residual disease (PRD) could facilitate its ...
Natalia Buenache   +31 more
wiley   +1 more source

The Effect of Protein Tagging on Aggregation and Phase Separation

open access: yesJournal of Cellular Biochemistry, Volume 127, Issue 6, June 2026.
ABSTRACT Protein tags are widely used for purification, solubilization, detection, and imaging, yet they can substantially alter protein self‐assembly. This interference is particularly significant for intrinsically disordered proteins and low‐complexity domains, whose aggregation and phase separation are mediated by weak multivalent interactions that ...
Harunobu Saito, Kenji Sugase
wiley   +1 more source

Home - About - Disclaimer - Privacy